April 2026
1. TEKE K, Ozer C, Yaprak Bayrak B, Reyhancan IA, et al
   Boron neutron capture therapy (BNCT) for experimental bladder cancer: systemic or intravesical approach.
   Br J Cancer. 2026 Apr 17. doi: 10.1038/s41416-026-03418.
   

   >> Share

   
   
2. XING Z, Xu H, Lin P, Hong Y, et al
   ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.
   Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03364.
   

   >> Share

   
   November 2024
3. ALEMAN A, Adrien L, Lopez-Serra L, Cordon-Cardo C, et al
   Editorial Expression of Concern: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays.
   Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02903.
   

   >> Share

   
   October 2024
4. LU JL, Ye YL, Zheng DD, Shi XY, et al
   Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guerin therapy.
   Br J Cancer. 2024 Oct 31. doi: 10.1038/s41416-024-02883.
   

   >> Share

   
   April 2024
5. JONES RJ, Crabb SJ, Linch M, Birtle AJ, et al
   Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
   Br J Cancer. 2024;130:897-907.
   

   >> Share

   
   March 2024
6. OUYANG Y, Zhong W, Xu P, Wang B, et al
   Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis.
   Br J Cancer. 2024;130:880-891.
   

   >> Share

   
   February 2024
7. ZHANG L, Zhang R, Jin D, Zhang T, et al
   Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer.
   Br J Cancer. 2024 Feb 8. doi: 10.1038/s41416-024-02598.
   

   >> Share

   
   
8. FONT A, Mellado B, Climent MA, Virizuela JA, et al
   Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
   Br J Cancer. 2024;130:434-441.
   

   >> Share

   
   January 2024
9. SU X, Jin K, Guo Q, Xu Z, et al
   Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
   Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02572.
   

   >> Share

   
   December 2023
10. VIERGEVER BJ, Raats DAE, Geurts V, Mullenders J, et al
    Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.
    Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02494.
    

    >> Share

    
    September 2023
11. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
    Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
    Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
    

    >> Share

    
    August 2023
12. LU J, Lai J, Xiao K, Peng S, et al
    A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study.
    Br J Cancer. 2023 Aug 4. doi: 10.1038/s41416-023-02383.
    

    >> Share

    
    July 2023
13. SHALA NK, Stenehjem JS, Babigumira R, Liu FC, et al
    Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers.
    Br J Cancer. 2023 Jul 18. doi: 10.1038/s41416-023-02357.
    

    >> Share

    
    June 2023
14. YAMAMOTO S, Kato M, Takeyama Y, Azuma Y, et al
    Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
    Br J Cancer. 2023;128:2197-2205.
    

    >> Share

    
    March 2023
15. VASDEV N
    Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02142.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share